Tyrphostin Ag 490

Tyrphostin Ag 490

SCHEMBL2279211

N#CC(=CC(=O)NCc1ccccc1)c1ccc(O)c(O)c1.N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.77
MEN1 O00255 9/20 0.77
KMT2A Q03164 9/20 0.77
ALDH1A1 P00352 6/20 0.77
HPGD P15428 6/20 0.77
MAPT P10636 6/20 0.77
TDP1 Q9NUW8 6/20 0.77
KDM4E B2RXH2 5/20 0.77
CYP3A4 P08684 5/20 0.77
ALOX15 P16050 5/20 0.77
ALOX12 P18054 5/20 0.77
MAPK1 P28482 5/20 0.77
RECQL P46063 5/20 0.77
BLM P54132 5/20 0.77
HSD17B10 Q99714 5/20 0.77
ERBB2 P04626 4/20 0.77
CYP1A2 P05177 4/20 0.77
TP53 P04637 4/20 0.77
NFKB1 P19838 4/20 0.77
PMP22 Q01453 4/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrphostin Ag 490 SCHEMBL2279210 0.88 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD
Tyrphostin Ag 490 SCHEMBL93683 0.88 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD
Tyrphostin Ag 490 SCHEMBL29379893 0.88 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD
SCHEMBL28514886 0.88 ALDH1A1 (0.54) EGFRMEN1KMT2AALDH1A1HPGD
Tyrphostin Ag 490 SCHEMBL93682 0.88 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD
Tyrphostin Ag 490 SCHEMBL17743575 0.88 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD
Tyrphostin Ag 490 SCHEMBL29351367 0.88 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD
SCHEMBL7378564 0.77 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD
Ls-104 SCHEMBL3956490 0.75 MAOB (1.00) EGFRMEN1KMT2AALDH1A1HPGD
SCHEMBL645291 0.75 EGFR (1.00) EGFRMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180460-B2 Amino pyrimidine derivatives NOVARTIS AG (CH) 2021-11-23 US disclosed
US-8791100-B2 Aryl benzylamine compounds NOVARTIS AG (CH) 2014-07-29 US disclosed
US-20130072396-A1 Transplant Rejection Markers NOVARTIS AG (CH) 2013-03-21 US disclosed
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180460-B2 Amino pyrimidine derivatives BTK, LCK, JAK1 EGFR 452/4885MEN1 4865/4885KMT2A 1083/4885
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS UGT2B7, NAT1, CYP2B6 EGFR 587/4885MEN1 3015/4885KMT2A 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.